Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem

Blood Cells, Molecules, and Diseases

Volumn 48, Issue 1, 2012, Pages 45-50

  Elstein, Deborah ^a   Altarescu, Gheona ^a   Maayan, Hannah ^a   Phillips, Mici ^a   Abrahamov, Aya ^a   Hadas Halpern, Irith ^a   Tiomkin, Maayan ^a   Zimran, Ari ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Enzyme replacement therapy; Gaucher disease; Imiglucerase; Switch over; Velaglucerase alfa

Indexed keywords

CHITOTRIOSIDASE; ELELYSO; IMIGLUCERASE; IMMUNOGLOBULIN G ANTIBODY; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY ACCESS PROGRAM; ENZYME ACTIVITY; GAUCHER DISEASE; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER WEIGHT; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SPLEEN; SPLEEN VOLUME; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; DRUG SUBSTITUTION; DRUG TOXICITY; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HUMANS; ISRAEL; LIVER; MALE; MIDDLE AGED; ORGAN SIZE; SPLEEN;

EID: 84855186853     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.09.009     Document Type: Article

References (31)

1. DeDuve C. From cytases to lysosomes. Fed. Proc. 1964, 23:1045-1049.
2. Brady R.O. The sphingolipidoses. N. Engl. J. Med. 1966, 275:312-318.
3. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 1991, 324:1464-1470.
4. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Enzyme therapy in Gaucher disease type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 1995, 122:33-39.
5. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., Foldes A.J., Schwartz A.J., Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995, 345:1479-1480.
6. Elstein D., Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009, 3:407-417.
7. Weinreb N.J., Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Rosenbloom B.E., Scott C.R., Wappner R.S., Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry. Am. J. Med. 2002, 113:112-119.
8. Charrow J., Dulisse B., Grabowski G.A., Weinreb N.J. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin. Genet. 2007, 71:205-211.
9. Andersson H., Kaplan P., Kacena K., Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008, 122:1182-1190.
10. Pastores G.M., Weinreb N.J., Aerts H., Andria G., Cox T.M., Giralt M., Grabowski G.A., Mistry P.K., Tylki-Szymańska A. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 2004, 41:4-14.
11. Weinreb N., Taylor J., Cox T., Yee J., vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am. J. Hematol. 2008, 83:890-895.
12. Sidransky E., Pastores G.M., Mori M. Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?. Genet. Med. 2009, 11:90-91.
13. de Fost M., Hollak C.E., Groener J.E., Aerts J.M., Maas M., Poll L.W., Wiersma M.G., Häussinger D., Brett S., Brill N., vom Dahl S. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006, 108:830-835.
14. Grabowski G.A., Kacena K., Cole J.A., Hollak C.E., Zhang L., Yee J., Mistry P.K., Zimran A., Charrow J., vom Dahl S. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet. Med. 2009, 11:92-100.
15. Hollak C.E., vom Dahl S., Aerts J.M., Belmatoug N., Bembi B., Cohen Y., Collin-Histed T., Deegan P., van Dussen L., Giraldo P., Mengel E., Michelakakis H., Manuel J., Hrebicek M., Parini R., Reinke J., di Rocco M., Pocovi M., Sa Miranda M.C., Tylki-Szymanska A., Zimran A., Cox T.M. Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis. 2010, 44:41-47.
16. Cox T.M. Recommendations for treating patients with Gaucher disease with emerging enzyme products. Blood Cells Mol. Dis. 2010, 44:84-85.
17. Zimran A., Loveday K., Fratazzi C., Elstein D. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol. Dis. 2007, 39:115-118.
18. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., Liberman Y., Freeman A., Zimran A., Galun E. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One 2009, 4:e4792.
19. Goldblatt J., Fletcher J.M., McGill J., Szer J., Wilson M. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol. Dis. 2011, 46:107-110.
20. Zimran A., Altarescu G., Elstein D. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol. Dis. 2011, 46:111-114.
21. Patlas M., Hadas-Halpern I., Abrahamov A., Zimran A., Elstein D. Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol. J. 2002, 3:17-20.
22. Zimran A., Hollak C.E., Abrahamov A., van Oers M.H., Kelly M., Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993, 82:1107-1109.
23. Hollak C.E.M., van Weely S., van Oers M.H.J., Aerts J.M.F.G. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 98:1288-1292.
24. Pastores G.M. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr. Opin. Invest. Drugs 2010, 11:472-478.
25. Zimran A., Altarescu G., Philips M., Attias D., Jmoudiak M., Deeb M., Wang N., Bhirangi K., Cohn G.M., Elstein D. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010, 115:4651-4656.
26. Sawkar A.R., Adamski-Werner S.L., Cheng W.C., Wong C.H., Beutler E., Zimmer K.P., Kelly J.W. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 2005, 12:1235-1244.
27. Brumshtein B., Salinas P., Peterson B., Chan V., Silman I., Sussman J.L., Savickas P.J., Robinson G.S., Futerman A.H. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010, 20:24-32.
28. Elstein D., Dweck A., Attias D., Hadas-Halpern I., Zevin S., Altarescu G., Aerts J.F., van Weely S., Zimran A. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007, 110:2296-2301.
29. Zimran A. How I treat Gaucher disease. Blood 2011, 118:1463-1471.
30. Lukina E., Watman N., Arreguin E.A., Banikazemi M., Dragosky M., Iastrebner M., Rosenbaum H., Phillips M., Pastores G.M., Rosenthal D.I., Kaper M., Singh T., Puga A.C., Bonate P.L., Peterschmitt M.J. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010, 116:893-899.
31. Zimran A., Pastores G.M., Tylki-Szymanska A., Hughes D., Elstein D., Mardach R., Eng C., Smith L., Heisel-Kurth M., Charrow J., Harmatz P., Fernhoff P., Rhead W., Longo N., Giraldo P., Zahrieh D., Crombez E., Grabowski G.A. 2-year efficacy and safety of velaglucerase alfa enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease (GD1) switching from imiglucerase. 18th ESGLD Workshop September 3-6 2011.